Supplementary Figure 4 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 4. Association between severity of treatment-related rash and steady-state exposure (day 15 AUC0-24) to pictilisib. (Gr=Grade).
Authors: Debashis Sarker, Joo Ern Ang, Richard Baird, Rebecca Kristeleit, Krunal Shah, Victor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362433656